Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
A Prospective, Single-arm, Open-label, Non-interventional, Multi-centre, Post Marketing Surveillance (PMS) Study of Cresemba to Evaluate Safety and Effectiveness in Patients With Invasive Aspergillosis or Invasive Mucormycosis in Korea
Sponsor: Pfizer
Listed as NCT04744454, this observational or N/A phase trial focuses on Aspergillosis and Mucormycosis and remains actively recruiting participants. Sponsored by Pfizer, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Jul 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Apr 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Nov 2021 — Apr 2023 [monthly]
Recruiting
-
Jun 2021 — Nov 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .